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Poor adherence with growth hormone (GH) therapy has been associated with worse 
clinical outcomes, which in children relates specifically to their linear growth and loss 
of quality of life. The “360° GH in Europe” meeting, held in Lisbon, Portugal, in June 
2016 and funded by Merck KGaA (Germany), examined many aspects of GH diseases. 
The three sessions, entitled “Short Stature Diagnosis and Referral,” “Optimizing Patient 
Management,” and “Managing Transition,” each benefited from three guest speaker 
presentations, followed by an open discussion and are reported as a manuscript, 
authored by the speakers. Reported here is a summary of the proceedings of the 
second session, which reviewed the determinants of GH therapy response, factors 
affecting GH therapy adherence and the development of innovative technologies to 
improve GH treatment in children. Response to GH therapy varies widely, particularly in 
regard to the underlying diagnosis, although there is little consensus on the definition of 
a poor response. If the growth response is seen to be less than expected, the possible 
reasons should be discussed with patients and their parents, including compliance with 
the therapy regimen. Understanding and addressing the multiple factors that influence 
adherence, in order to optimize GH therapy, requires a multi-disciplinary approach. 
Because therapy continues over many years, various healthcare professionals will be 
involved at different periods of the patient’s journey. The role of the injection device for 
GH therapy, frequent monitoring of response, and patient support are all important for 
maintaining adherence. New injection devices are incorporating electronic technologies 
for automated monitoring and recording of clinically relevant information on injections. 
Study results are indicating that such devices can at least maintain GH adherence; 
however, acceptance of novel devices needs to be assessed and there remains an 
on-going need for innovations.
Keywords: pediatric growth hormone response, adherence, growth hormone administration devices, digital 
health, personalized medicine, endocrinology
iNtrODUctiON
When growth hormone (GH) is administered to children with short stature, the growth response 
to treatment may vary widely between patients. This is partly related to the underlying cause of the 
short stature, but there are also other factors that are involved, including poor adherence to the 
therapy regimen itself. There are multiple causes for treatment non-adherence, some of which have 
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been addressed by adapting and improving the design of GH 
administration injection devices. However, resolving issues of 
GH non-adherence requires a much broader multi-disciplinary 
approach, which needs to be able to change as the young patient 
transitions through the different stages in their life. Monitoring 
of treatment adherence is, therefore, crucial and can be increas-
ingly achieved by the application of new technologies, including 
those directly integrated into the injection device itself. This 
report from the second session of the 360° GH in Europe meeting 
reviews the determinants of GH therapy response, the factors 
affecting GH therapy adherence and the innovative technologies 
that are being developed to improve these issues. The reports 
on the first and third sessions, on the diagnosis and referral of 
patients with short stature and on the transition of GH-treated 
patients from pediatric to adult care, are published in accompa-
nying articles (1, 2).
GH resPONDers versUs  
NON-resPONDers—iDeNtiFicAtiON  
AND MANAGeMeNt
In pediatric patients with short stature, one of the main 
determinants of response to GH treatment is the underlying 
diagnosis. Plotting GH secretion from stimulation tests versus 
sensitivity, defined as change in height standard deviation 
score (SDS) over time, shows a continuum of response (3, 4). 
This ranges from severe GH deficiency, with low secretion and 
good sensitivity, through to severe primary IGF-I deficiency, 
with good secretion and low sensitivity. However, the means 
of determining GH secretion remain equivocal, and sensitivity 
cannot be evaluated prior to treatment, but only at some time 
after GH initiation; it is usually derived from height change 
at 1 year. As a result, there is currently no consensus on how 
to separate groups of responders and non-responders to GH 
treatment, with wide variation seen within as well as between 
each of the diagnostic groups (3).
Various measures have been suggested to enable definition 
of a poor response to GH. A 1-year change in height SDS of 
<0.3 is not sufficiently different from the normal growth rate 
and is not a sufficiently accurate definition of a poor response. 
A cutoff height SDS change of 0.5 is more specific, corresponding 
to about 1.5 cm above normal annual growth at 2 years of age and 
about 3 cm above normal at 10 years of age. Whatever definition 
is used though, there remain a high number of patients defined 
as poor responders in all diagnostic groups, ranging from 10% 
to about 60% of GH-treated patients (3).
In a large US study, measurement of height velocity in the 
first year of treatment showed a marked difference according to 
age, with decreasing change in mean height velocity in patients 
who were older at GH initiation (5). The results indicated that a 
first-year height velocity more than 1 SD below the mean for age 
was an acceptable cutoff for a poor response. Height velocity data 
from patients with GH deficiency in the US study were shown 
to be in accord with results in the Pfizer International Growth 
(KIGS) database (6). However, height velocity minus 1 SD in the 
KIGS data corresponded to minus 2 SD in the US study because 
the GH deficiency was more severe for the US patients and the 
GH dose used for GH deficiency in the US is higher than in 
Europe.
It should be remembered though that not only GH sensitiv-
ity may differ in a patient, but also IGF sensitivity may vary. 
In a study that tried to remove the variation in GH response by 
adjusting the dose to achieve a target IGF-I SDS of either 0 or 
2, it was found that there were still wide differences in 1-year 
change in height SDS (7). Data for differing diagnoses were 
suggested to indicate varying degrees of both GH and IGF-I 
insensitivity; thus, the authors concluded that patients with dif-
ferent diagnoses may require different management strategies 
to optimize growth.
There are models that have been used to predict growth 
response prior to GH initiation (8). However, in patients with 
a predicted 1-year change in height SDS of <0.5, assessment of 
the observed change resulted in a large number of patients who 
had an actual height SDS change >0.5 (3). This suggests that 
these prediction models cannot be used to accurately predict 
patients with poor response prior to treatment. Nevertheless, 
if the observed response at 1  year for an individual patient 
is below the predicted response, this can be used to discuss 
the possible reasons with patients and their parents. There 
may be several reasons, such as an incorrect diagnosis of 
cause of short stature, occurrence of concomitant diseases, or 
unanticipated GH insensitivity (6). Alternatively, poor adher-
ence to a treatment regimen may be identified in a patient, 
and different management may be required in order to try to 
overcome this.
ADHereNce tO GH treAtMeNt— 
A PrActicAL APPrOAcH
Poor adherence with GH therapy has been demonstrated to be 
associated with worse clinical outcomes, specifically impaired 
linear growth in children (9). Treatment failure and loss of 
quality of life may result from non-adherence to GH regimens 
(10). However, the evidence base for assessing adherence to 
GH therapy remains rather weak, with relatively few studies 
and wide variation in their quality and definitions. A recent 
systematic review of published studies found estimates for 
pediatric non-adherence ranging from 5 to 82% (11), although 
it is generally evident that most patients are, at times, non-
adherent to some degree. A number of different factors have 
been identified that are known to influence treatment adher-
ence in general, including those relating to the patient, their 
underlying disease, and their understanding of the disease and 
the need for treatment, as well the healthcare professionals 
and the quality of the healthcare system supporting them. 
The type, nature, and route of administration of the treatment 
are also important factors that influence treatment adherence 
rates (11).
Understanding these factors may suggest ways in which GH 
therapy adherence could be improved. The treatment modal-
ity is crucial in affecting growth, and the efficacy, safety, and 
frequency of administration will directly affect adherence. 
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The healthcare system has to be efficient with follow-up and 
monitoring and be able to provide well-coordinated clinical 
practices. The physicians and other personnel involved in 
therapy need to have a good knowledge base of both the disease 
and the treatment options; this empowers them to help both the 
patients and their families. Underlying all of this is involvement 
of the patients and families in decision making; providing them 
with sufficient knowledge of the condition and the benefits/
risks of a therapy option is crucial for maintaining compliance 
of pediatric patients (12).
A good knowledge base allows optimization of therapy and 
this should be provided both at the introduction and during 
maintenance phases of a specified therapy. Information must be 
provided at the appropriate times, the expectations of everyone 
involved should be identified and understood, and concerns 
should be addressed as soon as they arise. Patients and families 
should be included in decision making, with interventions 
tailored to help them, in order to provide a consensus approach 
to therapy initiation and maintenance and achieve better out-
comes (10). Monitoring of adherence is also important to allow 
non-adherence to be tracked and assessed. Knowledge and 
understanding of the condition and treatments is particularly 
important as the young patient gets older, particularly as they 
transition from childhood to adolescence. Changes in require-
ments should be identified as soon as possible, enabling prob-
lems to be resolved more efficiently. Where adherence behavior 
becomes aberrant, a psychological approach enables recognition 
and resolving of issues that occur. Various models are avail-
able to address adherence, such as the Capability, Opportunity, 
Modification Behavior (COM-B) model, which has been applied 
in other therapy areas (13, 14).
It must be emphasized that optimizing GH therapy adher-
ence is not the sole responsibility of the patient or their family, 
nor of the prescribing pediatrician/physician. There needs to be 
a multi-disciplinary approach, involving a number of different 
healthcare professionals and allied agencies. While the pediatric 
endocrinologist and specialist endocrine nurses are central to 
this supportive role, pharmacists can also ensure timely and 
efficient drug dispensing, and clinical psychologists and play 
therapists may help with issues such as needle or injection 
phobia.
During a young patient’s treatment journey, multiple oppor-
tunities exist for reviewing adherence and resolving any issues 
that arise. This may start at the time of diagnosis and with the 
initiation of GH treatment, and should continue at all routine 
follow-up clinic visits thereafter. There are also specific devel-
opmental “milestone” opportunities where adherence may be 
assessed, including at onset of puberty and transition to ado-
lescence, moving from junior to high school, at completion of 
growth and transition to care as a young adult, and at the start 
of higher education (15). Where poor adherence is suspected, 
specific patient support packages can be put in place. This might 
include provision of further counseling, education, and training. 
Young patients may also change their preferences to a particular 
GH administration device, and, when this occurs, a change in 
GH injection device may be required. The application of incen-
tive or reward systems may be helpful when dealing with younger 
patients, including the use of calendar/reminder systems and 
other token reinforcement strategies. Finally, patient/family 
support groups can also provide invaluable advice and support 
regarding GH therapy.
reseArcH AND tecHNOLOGY tO  
HeLP AcHieve PAtieNt OUtcOMes
Almost 80% of European inhabitants now have access to the 
Internet (16), which has a huge economic impact, affects daily 
life and is enabling new trends in digital health. Miniaturized, 
wearable personal devices are becoming more common on a 
growing scale, with US sales of wearable bands increasing from 
17 million in 2014 to 23 million in 2015, and estimated to be 45 
million in 2017 (17).
Technological innovations have already been shown to be 
effective in several other areas of medicine. A computer-based 
service was associated with good compliance in patients with 
hypertension in 1994 (18) and, more recently, internet-based 
computer systems have improved adherence with diabetes medi-
cations (19) and psychotherapies (20). Mobile phone sys tem 
reminders have been used to improve adherence with therapies 
for diabetes (21, 22), HIV (23), and malaria (24). Smart watches 
and smart pill packages are also now being used for reminders 
and monitoring of medication intake, which also improves 
adherence (25). For asthma management in children, an inhaler 
with audiovisual reminders and electronic monitoring increased 
corticosteroid adherence to 84% compared with 30% in a control 
group, and was associated with improved asthma morbidity 
score (26).
With regard to GH therapy, the role of the injection device, 
frequent monitoring, and patient support are very important for 
maintaining adherence, and there is a need for automatic moni-
toring and recording of information on injections (10, 27, 28). 
There are already technological improvements being made in 
devices for GH administration. A questionnaire study in patients 
and physicians concluded that new GH administration devices 
needed to be reliable, simple to use, and cause minimal pain (29). 
Discussion with the patients and physicians regarding four dif-
ferent devices indicated that an electronic device was preferred 
to an existing automated device, a needle-free device or a dispos-
able injection device (29).
New injection devices are incorporating electronic moni-
toring systems that enable the physician to identify time and 
dose of administration. The only such device for GH treatment, 
with published information at present, is the easypod™, which 
is an electronic auto-injector for administration of GH (Saizen®, 
Merck KGaA, Darmstadt, Germany) that was launched in 2007. 
This is now approved for use in more than 40 countries and 
has shown high acceptance by both children and their parents 
(30). During testing, users were reported to have a good overall 
impression, with a majority expressing a preference to continue 
to use it (30). After the dose is pre-set by a physician or nurse, 
patients can then set the depth, speed, and duration of injections 
(31). The device can monitor times and doses administered, with 
number of doses remaining being displayed to allow patients to 
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better manage their schedule. The data can be automatically 
transmitted to the physician, who is able to assess adherence; 
however, patients retain ownership of their data. If adherence 
appears to decrease at any time, the physician can contact the 
patient and try to address any issues before GH effectiveness 
is lost. In a 3-month study in 824 children, adherence was 
considered good and was significantly better in treatment-naïve 
children just starting GH than in treatment-experienced chil-
dren (32). Interim data from a large observational study has also 
indicated a high rate of adherence with GH therapy using the 
device, with medians of 95–97% in Canada, France, and Nordic 
countries at 9 months (33).
Technological innovations can only help if they are accepted 
and used by patients and their caregivers. A literature review 
suggested that user acceptance of telemedicine services among 
physicians and patients accounted for up to 37% of the success 
of telemedicine services (34): technology accounted for 29%, 
organizational aspects for 13%, policy and legislation for 11%, 
and financing for 10%. Knowledge of factors that will enable an 
increase in this acceptance rate for GH treatment are currently 
lacking; solutions to address them include understanding the 
expectations of prescribers and patients for the technology, 
evidence for new GH treatment behavior changes that are 
enabled by new technologies and verification of whether pre-
scribers need a behavior change in order to leverage innovative 
solutions.
DiscUssiON sessiON
In order to overcome variation in the growth response to GH 
treatment, it has been suggested that IGF-I level could be used 
routinely to manage the administered dose. There remain safety 
issues with increasing the GH dose though, and patients should 
only be treated with the approved doses. IGF-I concentration 
can change reasonably quickly and a savvy adolescent may take 
injections only for a short time to increase IGF-I just before a 
clinic visit, to disguise non-adherence. In GH-deficient patients, 
normal levels of IGF-I and IGFBP-3 are reached in 4–7 days after 
starting GH therapy, so the approach in such possible cases may 
be to monitor the levels more frequently, rather than just at the 
routine visits, in order to judge adherence.
Continuous infusion of GH has also been suggested as a 
means to improve response, but the only published study on 
continuous infusion found no difference in response, although 
IGF-I increased to a significantly greater extent compared with 
once-daily injection (35). Investigational long-acting formula-
tions have been proposed to have the potential to increase 
adherence (36). A number of different long-acting GH prod-
ucts have been investigated, although few have shown sufficient 
efficacy and safety, and none are currently marketed except for 
one in China only (37). None of the published studies of long-
acting GH have shown an increase in adherence. However, 
novel devices that collect information regarding adherence 
may help to understand whether variation in response to GH 
relates to adherence or to other factors. Further adherence data 
that are being collected using electronic injection devices may 
help healthcare practitioners in the effective management of 
patients (38). In particular, an automated messaging function 
in a device can alert healthcare workers of reduced adherence 
of a patient and can provide an indication of different levels of 
importance.
Adherence could possibly be increased for some patients by 
reducing the number of daily injections (e.g., from 7 to 6 per 
week). Flexibility is considered a reasonable approach, but no 
studies have established whether the dose should be adjusted 
with fewer injections. While the outcome may be reduced with 
constantly missed doses, it is difficult to predict what outcome 
should be expected. However, response is diagnosis-specific, 
and reducing doses could possibly be less important for patients 
with short stature due to severe GH deficiency than for patients 
born SGA.
Whether patients get a choice on formulations and devices, 
or if physicians give only one choice, should be considered 
when assessing compliance with GH treatment (9). In the 
UK, patients are always given a complete choice of GH brands 
and devices; in contrast, it was noted that in Portugal some 
hospitals offer only one choice, while others offer all brands. 
In the United States, device preference for GH administration 
is at the discretion of the insurance company; demonstration 
of increased adherence according to the device used may 
provide additional information for insurance companies to 
allow alternative options for clients to choose their preferred 
device.
Frequency of alerts and the type of patients that should 
be closely monitored for adherence need to be established. 
The urgency of alerts is unlikely to be considered the same 
by patients as by healthcare providers, and physicians need to 
establish what clinical outcomes are desired. Some patients and 
their families may resent too much intrusion and may consider 
feedback on adherence to be over frequent because they do 
not consider the situation to be urgent. Patients and health-
care workers who are technically knowledgeable will accept 
adherence monitoring, but the clinical value still needs to be 
assessed. In adolescent patients with diabetes, for instance, text 
messaging has been shown to have little impact on adherence 
or outcome (39). Nevertheless, approaches such as the COM-B 
model could be effective in overcoming issues relating to poor 
adherence, and techniques to change behavior have been shown 
to be efficacious (14, 40).
Expectations of pediatric patients and their parents need to 
be assessed. There is a need to increase understanding of the 
management of expectations, from both clinical and psycho-
logical viewpoints. Expectations need to be established right 
from the start in order to get long-term adherence. When 
considered purely as height growth, there is a physiological 
decrease in apparent response to GH treatment over time; 
therefore, information about other benefits, such as metabolic 
effects and bone strength, should be conveyed as patients enter 
adolescence.
Guidelines on when to stop GH treatment also need to be 
identified. Psychological factors influencing the patients and 
their families need to be considered to see if these may be causing 
problems of adherence. If treatment is continued long-term, and 
particularly as adolescent patients enter transition to adult care, 
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then adherence should continue to be monitored over time and 
novel techniques and devices can help with this.
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